The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | Harnessing the benefits of CD34+ cells collected for double HSCT in patients with multiple myeloma
Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential uses for CD34+ cells collected for double hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma. Whilst modern apheresis techniques enable the collection of enough cells for double transplants, full usage of these cells rarely occurs. Additional uses for the apheresis products include salvage transplantation, especially in patients with long-term thrombocytopenia. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
